
Emyria (ASX:EMD)
Emyria Limited is a clinical services and drug development company focused on improving patient outcomes in neuroscience and mental health via a unique business model: Emyria Care: Deliver evidence-based and emerging therapies for mental health and other unmet needs across multiple sites (Empax Centres). Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients. Emyria Data is used to improve Emyria’s distinct therapy and drug development programs. Emyria Drug Discovery: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia for a range of mental health and select neuroscience indications.






